Lv1
46 积分 2023-10-16 加入
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
25天前
已完结
Reimagining human-centric drug development with new approach methodologies
1个月前
已完结
Computational Insights into the Regioselective Hydroxylation of Nirmatrelvir Metabolized by Cytochrome P450 3A4
1个月前
已完结
Practical Aspects of Flavin-Containing Monooxygenase-Mediated Metabolism
2个月前
已完结
AI turbocharges antibody hunt for binders with drug-like qualities
4个月前
已完结
Peptide-Tools–Web Server for Calculating Physicochemical Properties of Peptides
6个月前
已完结
Mechanistic insights into RNA cleavage by human Argonaute2–siRNA complex
6个月前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
6个月前
已完结
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
8个月前
已完结
AMP-activated protein kinase: the current landscape for drug development
8个月前
已完结
皖公网安备34019202002308
